Korean Drugmakers Seek Global Collaboration for Open Innovation
The Korea Biomedical Review reported that open innovation has become a major strategy for Korean pharmaceutical companies to develop new drugs. They are increasingly going beyond the border to collaborate with foreign companies or research institutes for global open innovation. Pharmaceutical industry watchers said there would be more cases of global open innovation in the future and that the move is related to domestic drugmakers’ entry into foreign markets.
Click here to read the full article.